Pharming Group N.V. (PHAR)
Pharming Statistics
Share Statistics
Pharming has 68.39M shares outstanding. The number of shares has increased by 0.73% in one year.
| Shares Outstanding | 68.39M |
| Shares Change (YoY) | 0.73% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 0.01% |
| Shares Floating | 64.91M |
| Failed to Deliver (FTD) Shares | 141 |
| FTD / Avg. Volume | 2.32% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -62.96 and the forward PE ratio is -269.67. Pharming's PEG ratio is -10.14.
| PE Ratio | -62.96 |
| Forward PE | -269.67 |
| PS Ratio | 2.34 |
| Forward PS | 1.5 |
| PB Ratio | 3.13 |
| P/FCF Ratio | -258.67 |
| PEG Ratio | -10.14 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Pharming.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.78, with a Debt / Equity ratio of 0.51.
| Current Ratio | 3.78 |
| Quick Ratio | 3.02 |
| Debt / Equity | 0.51 |
| Debt / EBITDA | 15.08 |
| Debt / FCF | -41.84 |
| Interest Coverage | -0.95 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $710.12K |
| Profits Per Employee | $-26.35K |
| Employee Count | 404 |
| Asset Turnover | 0.74 |
| Inventory Turnover | 0.64 |
Taxes
| Income Tax | 2.43M |
| Effective Tax Rate | -29.53% |
Stock Price Statistics
The stock price has increased by -13.16% in the last 52 weeks. The beta is 0.6, so Pharming's price volatility has been higher than the market average.
| Beta | 0.6 |
| 52-Week Price Change | -13.16% |
| 50-Day Moving Average | 8.53 |
| 200-Day Moving Average | 8.44 |
| Relative Strength Index (RSI) | 53.86 |
| Average Volume (20 Days) | 6.08K |
Income Statement
In the last 12 months, Pharming had revenue of 286.89M and earned -10.64M in profits. Earnings per share was -0.15.
| Revenue | 286.89M |
| Gross Profit | 252.72M |
| Operating Income | -8.32M |
| Net Income | -10.64M |
| EBITDA | 7.19M |
| EBIT | -8.32M |
| Earnings Per Share (EPS) | -0.15 |
Balance Sheet
The company has 53.04M in cash and 108.42M in debt, giving a net cash position of -55.38M.
| Cash & Cash Equivalents | 53.04M |
| Total Debt | 108.42M |
| Net Cash | -55.38M |
| Retained Earnings | -265.36M |
| Total Assets | 399.99M |
| Working Capital | 204.64M |
Cash Flow
In the last 12 months, operating cash flow was -1.79M and capital expenditures -796K, giving a free cash flow of -2.59M.
| Operating Cash Flow | -1.79M |
| Capital Expenditures | -796K |
| Free Cash Flow | -2.59M |
| FCF Per Share | 0 |
Margins
Gross margin is 88.09%, with operating and profit margins of -2.9% and -3.71%.
| Gross Margin | 88.09% |
| Operating Margin | -2.9% |
| Pretax Margin | -2.86% |
| Profit Margin | -3.71% |
| EBITDA Margin | 2.51% |
| EBIT Margin | -2.9% |
| FCF Margin | -0.9% |
Dividends & Yields
PHAR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for PHAR is $37, which is 334.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $37 |
| Price Target Difference | 334.8% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 2.3 |
| Piotroski F-Score | 5 |